All In Biotech

Drug Trial Radar · NCT03923374

Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes

Effects of Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes

Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Sep 15, 2018

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Senthil SadhasivamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA)
First posted
Apr 22, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution and infants at risk of significant neonatal abstinence syndrome (NAS).

Conditions

  • Opioid-use Disorder
  • Opioid Use, Unspecified
  • Buprenorphine Dependence

Interventions

  • Subutex / BuprenorphineDrug

    Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.

  • Fetal & Neonatal MRIDiagnostic test

    Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.

  • DNA/Genetic/Pharmacokenetic Blood DrawsDiagnostic test

    Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of opioid misuse severity using assessmentsTime frame: 5 years
  2. Pharmacological treatment for neonatal abstinence syndromeTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UPMC Children's Hospital

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.